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Background: Eptifibatide is used during PCI with weight-adjusted dosing for patients up to 121 kg. Patients above this weight receive the same 
fixed maximal dose. It is unknown if this dose provides adequate eptifibatide concentration (>1,600 ng/ml) or platelet inhibition in patients over 
121 kg. KILO tested two novel eptifibatide dosing regimens; an actual body weight-based dosing regimen (ABW) and an ideal weight-based dosing 
regimen (IBW) compared to standard dosing in patients weighing > 121 kg undergoing PCI.
Methods: Sixty-seven patients weighing ≥ 125 kg undergoing elective PCI with planned eptifibatide use were randomized to one of three 
eptifibatide dosing regimens: standard dosing, ABW dosing with no upper threshold, or IBW dosing. Ideal body weight (IBW) was calculated as 50 + 
2.3 kg per inch over 5 ft for men and 45.5 + 2.3 kg per inch over 5 ft for women. Boluses of 180 mcg/kg were given 10 minutes apart, followed by a 
2.0 mcg/kg/min infusion. Plasma eptifibatide concentrations were drawn at steady state and 12-18 hours after the initiation of the infusion. Platelet 
aggregation was assessed using the Ultegra Rapid Platelet Function Analyzer (PFA) at baseline and 10 min after the second eptifibatide bolus.
Results: Sixty-seven patients were randomized to standard (n=22), ABW (n=23), or IBW dosing (n=22). The median (25th, 75th) steady state 
plasma eptifibatide concentrations were 1660 ng/mL (1345-2315 ng/mL) for standard, 1780 ng/mL (1510-2350 ng/mL) for ABW; and 1055 ng/
mL (738-1405 ng/mL) for IBW dosing. Ten-minute median (25th, 75th) platelet aggregation units were 7 (0-21) for standard, 2 (0-8) for ABW, and 
14 (8-20) for IBW dosing. There were no differences in bleeding.
Conclusions: Actual body weight based eptifibatide dosing leads to higher steady state concentrations and greater suppression of platelet 
aggregation than standard or IBW dosing in obese patients undergoing PCI. Actual body weight dosing may be preferable to currently recommended 
dosing and should be considered in the obese. Further study is warranted to define the optimal dosing of eptifibatide in obese patients.
